EICHOR
● Terminated
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Condition: Cervical Carcinoma · Sponsor: Iovance Biotherapeutics, Inc.
About this study
Prospective, multicenter, multiple cohort, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145), with or without pembrolizumab, followed by IL-2 after a non-myeloablative lymphodepletion (NMA-LD) preparative regimen for the treatment of participants with recurrent, metastatic, or persistent cervical carcinoma.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (43)
| St. Joseph's Hospital and Medical Center Center For Women's Health | Phoenix, Arizona, United States | — |
| University of Southern California | Los Angeles, California, United States | — |
| University of California San Diego | San Diego, California, United States | — |
| Sylvester Comprehensive Cancer Center | Miami, Florida, United States | — |
| University of Florida Health Cancer Center | Orlando, Florida, United States | — |
| University of South Florida H. Lee Moffitt Cancer Center and Research Institute | Tampa, Florida, United States | — |
| Augusta University | Augusta, Georgia, United States | — |
| University of Chicago | Chicago, Illinois, United States | — |
| James Graham Brown Cancer Center | Louisville, Kentucky, United States | — |
| LSU Health Sciences Center | New Orleans, Louisiana, United States | — |
| The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore, Maryland, United States | — |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | — |
+ 31 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.